Siren Biotechnology Awarded $8M Grant - Jun 26

The Story

Siren Biotechnology said it was awarded an $8 million non-dilutive grant from the California Institute for Regenerative Medicine, or CIRM, to support clinical development of SRN-101 in high-grade glioma. The funding announcement was made June 26 and targets next-stage clinical work for the SRN-101 program.

Why It Matters For Your Portfolio

• $8 million in non-dilutive funding, designated for SRN-101 clinical development, gives the program dedicated capital without issuing equity.
• The award comes from CIRM, a state-backed fund focused on regenerative medicine, which can signal external validation for SRN-101 in high-grade glioma.
• Program-focused financing may lessen immediate pressure on corporate cash needs tied to SRN-101, limiting the need for near-term dilutive financing for this asset.

The Trade

Who should care? Long-term biotech investors and traders tracking clinical milestones for SRN-101 will want to note this funding as a catalyst for continued development. Watch for company updates on trial starts, enrollment milestones, and CIRM milestone reports as the next material triggers for news flow.